Akgor, UtkuAyhan, AliShushkevich, AlexanderOzdal, BulentAngelou, KyveliAkbayir, OzgurKaidarova, DilyaraUlrikh, ElenaStepanyan, ArtemOrtac, FiratAliyev, ShamistanOzgul, NejatTaranenka, SiarheiHaberal, AliSalman, CoskunSeyhan, AlperSelcuk, IlkerHaidopoulos, DimitriosAkilli, HuseyinBolatbekova, RaikhanAlaverdyan, AregTaskin, SalihMurshudova, SabinaBatur, MeltemBerlev, IgorGultekin, Murat2022-12-012022-12-0120220020-7292http://hdl.handle.net/11727/8194Objective To evaluate the feasibility and oncological safety of ovarian preservation in early stage endometrial adenocarcinoma (EC) patients aged 40 and below. Methods A total of 11 institutions from eight countries participated in the study. 169 of 5898 patients aged <= 40 years were eligible for the study. Patients with EC treated between March 2007 and January 2019 were retrospectively assessed. Results The median duration of follow-up after EC diagnosis was 59 months (4-187). Among 169 participants, ovarian preservation surgery (OPS) was performed in 54 (31.9%), and BSO was performed in 115 (68.1%) patients. Although patients younger than 30 years of age were more likely to have OPS than patients aged 30 to 40 years (20.4% vs. 9.6%, P = 0.021), there was no significant difference by the mean age. There were no other relevant baseline differences between OPS and BSO groups. The Kaplan-Meier analysis revealed no difference in either the overall survival (P = 0.955) or recurrence-free survival (P = 0.068) among patients who underwent OPS, and BSO. Conclusion OPS appears to be safe without having any adverse impact on survival in women aged <= 40 years with FIGO Stage I EC.enginfo:eu-repo/semantics/closedAccessearly-stageendometrial cancerovarian preservationyoung womenarticle15925505560007825206000012-s2.0-85128040250